Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 50 entries
Sorted by: Best Match Show Resources per page
Alternate proof of the optical theorem for impenetrable targets.

The Journal of the Acoustical Society of America

Kriegsmann GA.
PMID: 16454259
J Acoust Soc Am. 2006 Jan;119(1):31-2. doi: 10.1121/1.2139071.

The optical theorem is proven for impenetrable targets without using the method of stationary phase. The proof depends upon the divergence theorem, the Helmholtz representation of the scattered field, and the law of cosines.

Cite
Kriegsmann GA. Alternate proof of the optical theorem for impenetrable targets. J Acoust Soc Am. 2006;119(1):31-2doi: 10.1121/1.2139071.
Kriegsmann, G. A. (2006). Alternate proof of the optical theorem for impenetrable targets. The Journal of the Acoustical Society of America, 119(1), 31-2. https://doi.org/10.1121/1.2139071
Kriegsmann, G A. "Alternate proof of the optical theorem for impenetrable targets." The Journal of the Acoustical Society of America vol. 119,1 (2006): 31-2. doi: https://doi.org/10.1121/1.2139071
Kriegsmann GA. Alternate proof of the optical theorem for impenetrable targets. J Acoust Soc Am. 2006 Jan;119(1):31-2. doi: 10.1121/1.2139071. PMID: 16454259.
Copy Download .nbib Format: NLM
Correlation of quantitative histopathological morphology and quantitative radiological analysis during aseptic loosening of hip endoprostheses.

Journal of applied biomaterials & biomechanics : JABB

Bertz S, Kriegsmann J, Eckardt A, Delank KS, Drees P, Hansen T, Otto M.
PMID: 20799201
J Appl Biomater Biomech. 2006 Sep-Dec;4(3):153-64.

OBJECTIVE: Aseptic hip prosthesis loosening is the most important long-term complication in total hip arthroplasty. Polyethylene (PE) wear is the dominant etiologic factor in aseptic loosening, which together with other factors induces mechanisms resulting in bone loss, and finally...

Cite
Bertz S, Kriegsmann J, Eckardt A, et al. Correlation of quantitative histopathological morphology and quantitative radiological analysis during aseptic loosening of hip endoprostheses. J Appl Biomater Biomech. 2006;4(3):153-64
Bertz, S., Kriegsmann, J., Eckardt, A., Delank, K. S., Drees, P., Hansen, T., & Otto, M. (2006). Correlation of quantitative histopathological morphology and quantitative radiological analysis during aseptic loosening of hip endoprostheses. Journal of applied biomaterials & biomechanics : JABB, 4(3), 153-64.
Bertz, S, et al. "Correlation of quantitative histopathological morphology and quantitative radiological analysis during aseptic loosening of hip endoprostheses." Journal of applied biomaterials & biomechanics : JABB vol. 4,3 (2006): 153-64.
Bertz S, Kriegsmann J, Eckardt A, Delank KS, Drees P, Hansen T, Otto M. Correlation of quantitative histopathological morphology and quantitative radiological analysis during aseptic loosening of hip endoprostheses. J Appl Biomater Biomech. 2006 Sep-Dec;4(3):153-64. PMID: 20799201.
Copy Download .nbib Format: NLM
The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma.

Oncoimmunology

Awwad MHS, Kriegsmann K, Plaumann J, Benn M, Hillengass J, Raab MS, Bertsch U, Munder M, Weisel K, Salwender HJ, Hänel M, Fenk R, Dürig J, Müller-Tidow C, Goldschmidt H, Hundemer M.
PMID: 30288348
Oncoimmunology. 2018 Aug 01;7(10):e1486356. doi: 10.1080/2162402X.2018.1486356. eCollection 2018.

No abstract available.

Cite
Awwad MHS, Kriegsmann K, Plaumann J, et al. The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma. Oncoimmunology. 2018;7(10):e1486356doi: 10.1080/2162402X.2018.1486356.
Awwad, M. H. S., Kriegsmann, K., Plaumann, J., Benn, M., Hillengass, J., Raab, M. S., Bertsch, U., Munder, M., Weisel, K., Salwender, H. J., Hänel, M., Fenk, R., Dürig, J., Müller-Tidow, C., Goldschmidt, H., & Hundemer, M. (2018). The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma. Oncoimmunology, 7(10), e1486356. https://doi.org/10.1080/2162402X.2018.1486356
Awwad, Mohamed H S, et al. "The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma." Oncoimmunology vol. 7,10 (2018): e1486356. doi: https://doi.org/10.1080/2162402X.2018.1486356
Awwad MHS, Kriegsmann K, Plaumann J, Benn M, Hillengass J, Raab MS, Bertsch U, Munder M, Weisel K, Salwender HJ, Hänel M, Fenk R, Dürig J, Müller-Tidow C, Goldschmidt H, Hundemer M. The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma. Oncoimmunology. 2018 Aug 01;7(10):e1486356. doi: 10.1080/2162402X.2018.1486356. eCollection 2018. PMID: 30288348; PMCID: PMC6169592.
Copy Download .nbib Format: NLM
Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma.

Frontiers in oncology

Fisch D, Bozorgmehr F, Kazdal D, Kuon J, Klotz LV, Shah R, Eichhorn F, Kriegsmann M, Schneider MA, Muley T, Stenzinger A, Bischoff H, Christopoulos P.
PMID: 34307143
Front Oncol. 2021 Jul 08;11:673901. doi: 10.3389/fonc.2021.673901. eCollection 2021.

BACKGROUND: Large-cell neuroendocrine lung carcinoma (LCNEC) is a rare pulmonary neoplasm with poor prognosis and limited therapeutic options.METHODS: We retrospectively analyzed all patients with metastatic LCNEC in the records of a large German academic center since 2010.RESULTS: 191 patients...

Cite
Fisch D, Bozorgmehr F, Kazdal D, et al. Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma. Front Oncol. 2021;11:673901doi: 10.3389/fonc.2021.673901.
Fisch, D., Bozorgmehr, F., Kazdal, D., Kuon, J., Klotz, L. V., Shah, R., Eichhorn, F., Kriegsmann, M., Schneider, M. A., Muley, T., Stenzinger, A., Bischoff, H., & Christopoulos, P. (2021). Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma. Frontiers in oncology, 11673901. https://doi.org/10.3389/fonc.2021.673901
Fisch, David, et al. "Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma." Frontiers in oncology vol. 11 (2021): 673901. doi: https://doi.org/10.3389/fonc.2021.673901
Fisch D, Bozorgmehr F, Kazdal D, Kuon J, Klotz LV, Shah R, Eichhorn F, Kriegsmann M, Schneider MA, Muley T, Stenzinger A, Bischoff H, Christopoulos P. Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma. Front Oncol. 2021 Jul 08;11:673901. doi: 10.3389/fonc.2021.673901. eCollection 2021. PMID: 34307143; PMCID: PMC8295750.
Copy Download .nbib Format: NLM
Accuracy and Reliability of Internet Resources for Information on Monoclonal Gammopathy of Undetermined Significance-What Information Is out There for Our Patients?.

Cancers

Kreutzer EP, Sauer S, Kriegsmann M, Staemmler H, Egerer G, Kriegsmann K.
PMID: 34572733
Cancers (Basel). 2021 Sep 07;13(18). doi: 10.3390/cancers13184508.

BACKGROUND: Online information gathering can increase patients' engagement in decision-making. The quality of online resources available for monoclonal gammopathy of undetermined significance (MGUS) was evaluated.METHODS: 900 websites from Google, Bing, Yahoo, and 150 YouTube videos were assessed.RESULTS: The websites...

Cite
Kreutzer EP, Sauer S, Kriegsmann M, et al. Accuracy and Reliability of Internet Resources for Information on Monoclonal Gammopathy of Undetermined Significance-What Information Is out There for Our Patients?. Cancers (Basel). 2021;13(18)doi: 10.3390/cancers13184508.
Kreutzer, E. P., Sauer, S., Kriegsmann, M., Staemmler, H., Egerer, G., & Kriegsmann, K. (2021). Accuracy and Reliability of Internet Resources for Information on Monoclonal Gammopathy of Undetermined Significance-What Information Is out There for Our Patients?. Cancers, 13(18), . https://doi.org/10.3390/cancers13184508
Kreutzer, Emma Pauline, et al. "Accuracy and Reliability of Internet Resources for Information on Monoclonal Gammopathy of Undetermined Significance-What Information Is out There for Our Patients?." Cancers vol. 13,18 (2021). doi: https://doi.org/10.3390/cancers13184508
Kreutzer EP, Sauer S, Kriegsmann M, Staemmler H, Egerer G, Kriegsmann K. Accuracy and Reliability of Internet Resources for Information on Monoclonal Gammopathy of Undetermined Significance-What Information Is out There for Our Patients?. Cancers (Basel). 2021 Sep 07;13(18). doi: 10.3390/cancers13184508. PMID: 34572733; PMCID: PMC8465467.
Copy Download .nbib Format: NLM
Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis.

Cancers

Eichhorn F, Kriegsmann M, Klotz LV, Kriegsmann K, Muley T, Zgorzelski C, Christopoulos P, Winter H, Eichhorn ME.
PMID: 33922610
Cancers (Basel). 2021 Apr 23;13(9). doi: 10.3390/cancers13092046.

The programmed death-ligand 1 (PD-L1) plays a crucial role in immunomodulatory treatment concepts for end-stage non-small cell lung cancer (NSCLC). To date, its prognostic significance in patients with curative surgical treatment but regional nodal metastases, reflecting tumor spread beyond...

Cite
Eichhorn F, Kriegsmann M, Klotz LV, et al. Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis. Cancers (Basel). 2021;13(9)doi: 10.3390/cancers13092046.
Eichhorn, F., Kriegsmann, M., Klotz, L. V., Kriegsmann, K., Muley, T., Zgorzelski, C., Christopoulos, P., Winter, H., & Eichhorn, M. E. (2021). Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis. Cancers, 13(9), . https://doi.org/10.3390/cancers13092046
Eichhorn, Florian, et al. "Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis." Cancers vol. 13,9 (2021). doi: https://doi.org/10.3390/cancers13092046
Eichhorn F, Kriegsmann M, Klotz LV, Kriegsmann K, Muley T, Zgorzelski C, Christopoulos P, Winter H, Eichhorn ME. Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis. Cancers (Basel). 2021 Apr 23;13(9). doi: 10.3390/cancers13092046. PMID: 33922610; PMCID: PMC8122862.
Copy Download .nbib Format: NLM
Interferon Regulatory Factor 9 Promotes Lung Cancer Progression via Regulation of Versican.

Cancers

Brunn D, Turkowski K, Günther S, Weigert A, Muley T, Kriegsmann M, Winter H, Dammann RH, Stathopoulos GT, Thomas M, Guenther A, Grimminger F, Pullamsetti SS, Seeger W, Savai R.
PMID: 33430083
Cancers (Basel). 2021 Jan 08;13(2). doi: 10.3390/cancers13020208.

Transcription factors can serve as links between tumor microenvironment signaling and oncogenesis. Interferon regulatory factor 9 (IRF9) is recruited and expressed upon interferon stimulation and is dependent on cofactors that exert in tumor-suppressing or oncogenic functions via the JAK-STAT...

Cite
Brunn D, Turkowski K, Günther S, et al. Interferon Regulatory Factor 9 Promotes Lung Cancer Progression via Regulation of Versican. Cancers (Basel). 2021;13(2)doi: 10.3390/cancers13020208.
Brunn, D., Turkowski, K., Günther, S., Weigert, A., Muley, T., Kriegsmann, M., Winter, H., Dammann, R. H., Stathopoulos, G. T., Thomas, M., Guenther, A., Grimminger, F., Pullamsetti, S. S., Seeger, W., & Savai, R. (2021). Interferon Regulatory Factor 9 Promotes Lung Cancer Progression via Regulation of Versican. Cancers, 13(2), . https://doi.org/10.3390/cancers13020208
Brunn, David, et al. "Interferon Regulatory Factor 9 Promotes Lung Cancer Progression via Regulation of Versican." Cancers vol. 13,2 (2021). doi: https://doi.org/10.3390/cancers13020208
Brunn D, Turkowski K, Günther S, Weigert A, Muley T, Kriegsmann M, Winter H, Dammann RH, Stathopoulos GT, Thomas M, Guenther A, Grimminger F, Pullamsetti SS, Seeger W, Savai R. Interferon Regulatory Factor 9 Promotes Lung Cancer Progression via Regulation of Versican. Cancers (Basel). 2021 Jan 08;13(2). doi: 10.3390/cancers13020208. PMID: 33430083; PMCID: PMC7827113.
Copy Download .nbib Format: NLM
Germline Genetic Variants of the Renin-Angiotensin System, Hypoxia and Angiogenesis in Non-Small Cell Lung Cancer Progression: Discovery and Validation Studies.

Cancers

Catarata MJ, Medeiros R, Oliveira MJ, Pêgo A, Frade JG, Martins MF, Robalo Cordeiro C, Herth FJF, Thomas M, Kriegsmann M, Meister M, Schneider MA, Muley T, Ribeiro R.
PMID: 33353148
Cancers (Basel). 2020 Dec 18;12(12). doi: 10.3390/cancers12123834.

INTRODUCTION: The renin-angiotensin system (RAS) is involved in cell proliferation, immunoinflammatory response, hypoxia and angiogenesis, which are critical biological processes in lung cancer. Our aim was to study the association of putatively functional genetic polymorphisms in genes coding for...

Cite
Catarata MJ, Medeiros R, Oliveira MJ, et al. Germline Genetic Variants of the Renin-Angiotensin System, Hypoxia and Angiogenesis in Non-Small Cell Lung Cancer Progression: Discovery and Validation Studies. Cancers (Basel). 2020;12(12)doi: 10.3390/cancers12123834.
Catarata, M. J., Medeiros, R., Oliveira, M. J., Pêgo, A., Frade, J. G., Martins, M. F., Robalo Cordeiro, C., Herth, F. J. F., Thomas, M., Kriegsmann, M., Meister, M., Schneider, M. A., Muley, T., & Ribeiro, R. (2020). Germline Genetic Variants of the Renin-Angiotensin System, Hypoxia and Angiogenesis in Non-Small Cell Lung Cancer Progression: Discovery and Validation Studies. Cancers, 12(12), . https://doi.org/10.3390/cancers12123834
Catarata, Maria Joana, et al. "Germline Genetic Variants of the Renin-Angiotensin System, Hypoxia and Angiogenesis in Non-Small Cell Lung Cancer Progression: Discovery and Validation Studies." Cancers vol. 12,12 (2020). doi: https://doi.org/10.3390/cancers12123834
Catarata MJ, Medeiros R, Oliveira MJ, Pêgo A, Frade JG, Martins MF, Robalo Cordeiro C, Herth FJF, Thomas M, Kriegsmann M, Meister M, Schneider MA, Muley T, Ribeiro R. Germline Genetic Variants of the Renin-Angiotensin System, Hypoxia and Angiogenesis in Non-Small Cell Lung Cancer Progression: Discovery and Validation Studies. Cancers (Basel). 2020 Dec 18;12(12). doi: 10.3390/cancers12123834. PMID: 33353148; PMCID: PMC7766842.
Copy Download .nbib Format: NLM
Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion.

Cancer cell

Lan Y, Moustafa M, Knoll M, Xu C, Furkel J, Lazorchak A, Yeung TL, Hasheminasab SM, Jenkins MH, Meister S, Yu H, Schlegel J, Marelli B, Tang Z, Qin G, Klein C, Qi J, Zhou C, Locke G, Krunic D, Derner MG, Schwager C, Fontana RE, Kriegsmann K, Jiang F, Rein K, Kriegsmann M, Debus J, Lo KM, Abdollahi A.
PMID: 34506739
Cancer Cell. 2021 Oct 11;39(10):1388-1403.e10. doi: 10.1016/j.ccell.2021.08.008. Epub 2021 Sep 09.

Localized radiotherapy (RT) induces an immunogenic antitumor response that is in part counterbalanced by activation of immune evasive and tissue remodeling processes, e.g., via upregulation of programmed cell death-ligand 1 (PD-L1) and transforming growth factor β (TGF-β). We report...

Cite
Lan Y, Moustafa M, Knoll M, et al. Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion. Cancer Cell. 2021;39(10):1388-1403.e10doi: 10.1016/j.ccell.2021.08.008.
Lan, Y., Moustafa, M., Knoll, M., Xu, C., Furkel, J., Lazorchak, A., Yeung, T. L., Hasheminasab, S. M., Jenkins, M. H., Meister, S., Yu, H., Schlegel, J., Marelli, B., Tang, Z., Qin, G., Klein, C., Qi, J., Zhou, C., Locke, G., Krunic, D., Derner, M. G., Schwager, C., Fontana, R. E., Kriegsmann, K., Jiang, F., Rein, K., Kriegsmann, M., Debus, J., Lo, K. M., & Abdollahi, A. (2021). Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion. Cancer cell, 39(10), 1388-1403.e10. https://doi.org/10.1016/j.ccell.2021.08.008
Lan, Yan, et al. "Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion." Cancer cell vol. 39,10 (2021): 1388-1403.e10. doi: https://doi.org/10.1016/j.ccell.2021.08.008
Lan Y, Moustafa M, Knoll M, Xu C, Furkel J, Lazorchak A, Yeung TL, Hasheminasab SM, Jenkins MH, Meister S, Yu H, Schlegel J, Marelli B, Tang Z, Qin G, Klein C, Qi J, Zhou C, Locke G, Krunic D, Derner MG, Schwager C, Fontana RE, Kriegsmann K, Jiang F, Rein K, Kriegsmann M, Debus J, Lo KM, Abdollahi A. Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion. Cancer Cell. 2021 Oct 11;39(10):1388-1403.e10. doi: 10.1016/j.ccell.2021.08.008. Epub 2021 Sep 09. PMID: 34506739.
Copy Download .nbib Format: NLM
Canonical NF-κB Promotes Lung Epithelial Cell Tumour Growth by Downregulating the Metastasis Suppressor CD82 and Enhancing Epithelial-to-Mesenchymal Cell Transition.

Cancers

Roupakia E, Chavdoula E, Karpathiou G, Vatsellas G, Chatzopoulos D, Mela A, Gillette JM, Kriegsmann K, Kriegsmann M, Batistatou A, Goussia A, Marcu KB, Karteris E, Klinakis A, Kolettas E.
PMID: 34503110
Cancers (Basel). 2021 Aug 26;13(17). doi: 10.3390/cancers13174302.

BACKGROUND: The development of non-small cell lung cancer (NSCLC) involves the progressive accumulation of genetic and epigenetic changes. These include somatic oncogenic METHODS: Human NSCLC cells were used to knock-down RelA/p65 (RelA/p65RESULTS: RelA/p65CONCLUSIONS: Canonical NF-κB signalling promotes NSCLC, in...

Cite
Roupakia E, Chavdoula E, Karpathiou G, et al. Canonical NF-κB Promotes Lung Epithelial Cell Tumour Growth by Downregulating the Metastasis Suppressor CD82 and Enhancing Epithelial-to-Mesenchymal Cell Transition. Cancers (Basel). 2021;13(17)doi: 10.3390/cancers13174302.
Roupakia, E., Chavdoula, E., Karpathiou, G., Vatsellas, G., Chatzopoulos, D., Mela, A., Gillette, J. M., Kriegsmann, K., Kriegsmann, M., Batistatou, A., Goussia, A., Marcu, K. B., Karteris, E., Klinakis, A., & Kolettas, E. (2021). Canonical NF-κB Promotes Lung Epithelial Cell Tumour Growth by Downregulating the Metastasis Suppressor CD82 and Enhancing Epithelial-to-Mesenchymal Cell Transition. Cancers, 13(17), . https://doi.org/10.3390/cancers13174302
Roupakia, Eugenia, et al. "Canonical NF-κB Promotes Lung Epithelial Cell Tumour Growth by Downregulating the Metastasis Suppressor CD82 and Enhancing Epithelial-to-Mesenchymal Cell Transition." Cancers vol. 13,17 (2021). doi: https://doi.org/10.3390/cancers13174302
Roupakia E, Chavdoula E, Karpathiou G, Vatsellas G, Chatzopoulos D, Mela A, Gillette JM, Kriegsmann K, Kriegsmann M, Batistatou A, Goussia A, Marcu KB, Karteris E, Klinakis A, Kolettas E. Canonical NF-κB Promotes Lung Epithelial Cell Tumour Growth by Downregulating the Metastasis Suppressor CD82 and Enhancing Epithelial-to-Mesenchymal Cell Transition. Cancers (Basel). 2021 Aug 26;13(17). doi: 10.3390/cancers13174302. PMID: 34503110; PMCID: PMC8428346.
Copy Download .nbib Format: NLM
Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment.

Cancers

Kriegsmann K, Hundemer M, Hofmeister-Mielke N, Reichert P, Manta CP, Awwad MHS, Sauer S, Bertsch U, Besemer B, Fenk R, Hänel M, Munder M, Weisel KC, Blau IW, Neubauer A, Müller-Tidow C, Raab MS, Goldschmidt H, Huhn S, For The German-Speaking Myeloma Multicenter Group Gmmg.
PMID: 32824635
Cancers (Basel). 2020 Aug 18;12(8). doi: 10.3390/cancers12082322.

In order to meet the challenges in data evaluation and comparability between studies in multiple myeloma (MM) minimal residual disease (MRD) assessment, the goal of the current study was to provide a step-by-step evaluation of next-generation sequencing (NGS) and...

Cite
Kriegsmann K, Hundemer M, Hofmeister-Mielke N, et al. Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment. Cancers (Basel). 2020;12(8)doi: 10.3390/cancers12082322.
Kriegsmann, K., Hundemer, M., Hofmeister-Mielke, N., Reichert, P., Manta, C. P., Awwad, M. H. S., Sauer, S., Bertsch, U., Besemer, B., Fenk, R., Hänel, M., Munder, M., Weisel, K. C., Blau, I. W., Neubauer, A., Müller-Tidow, C., Raab, M. S., Goldschmidt, H., Huhn, S., & For The German-Speaking Myeloma Multicenter Group Gmmg. (2020). Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment. Cancers, 12(8), . https://doi.org/10.3390/cancers12082322
Kriegsmann, Katharina, et al. "Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment." Cancers vol. 12,8 (2020). doi: https://doi.org/10.3390/cancers12082322
Kriegsmann K, Hundemer M, Hofmeister-Mielke N, Reichert P, Manta CP, Awwad MHS, Sauer S, Bertsch U, Besemer B, Fenk R, Hänel M, Munder M, Weisel KC, Blau IW, Neubauer A, Müller-Tidow C, Raab MS, Goldschmidt H, Huhn S, For The German-Speaking Myeloma Multicenter Group Gmmg. Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment. Cancers (Basel). 2020 Aug 18;12(8). doi: 10.3390/cancers12082322. PMID: 32824635; PMCID: PMC7464347.
Copy Download .nbib Format: NLM
Thermodynamics of CeSiO.

Inorganic chemistry

Strzelecki AC, Bourgeois C, Kriegsman KW, Estevenon P, Wei N, Szenknect S, Mesbah A, Wu D, Ewing RC, Dacheux N, Guo X.
PMID: 32871073
Inorg Chem. 2020 Sep 21;59(18):13174-13183. doi: 10.1021/acs.inorgchem.0c01476. Epub 2020 Sep 01.

Zircon (ZrSiO

Cite
Strzelecki AC, Bourgeois C, Kriegsman KW, et al. Thermodynamics of CeSiO. Inorg Chem. 2020;59(18):13174-13183doi: 10.1021/acs.inorgchem.0c01476.
Strzelecki, A. C., Bourgeois, C., Kriegsman, K. W., Estevenon, P., Wei, N., Szenknect, S., Mesbah, A., Wu, D., Ewing, R. C., Dacheux, N., & Guo, X. (2020). Thermodynamics of CeSiO. Inorganic chemistry, 59(18), 13174-13183. https://doi.org/10.1021/acs.inorgchem.0c01476
Strzelecki, Andrew C, et al. "Thermodynamics of CeSiO." Inorganic chemistry vol. 59,18 (2020): 13174-13183. doi: https://doi.org/10.1021/acs.inorgchem.0c01476
Strzelecki AC, Bourgeois C, Kriegsman KW, Estevenon P, Wei N, Szenknect S, Mesbah A, Wu D, Ewing RC, Dacheux N, Guo X. Thermodynamics of CeSiO. Inorg Chem. 2020 Sep 21;59(18):13174-13183. doi: 10.1021/acs.inorgchem.0c01476. Epub 2020 Sep 01. PMID: 32871073.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 50 entries